Synthesis of benzopyran derivatives as PPARα and/or PPARγ activators.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 12 2019
Historique:
received: 23 09 2019
accepted: 10 10 2019
pubmed: 11 11 2019
medline: 24 9 2020
entrez: 10 11 2019
Statut: ppublish

Résumé

We describe the synthesis of 26 compounds, small polycerasoidol analogs, that are Lipinski's rule-of-five compliant. In order to confirm key structural features to activate PPARα and/or PPARγ, we have adopted structural modifications in the following parts: (i) the benzopyran core (hydrophobic nucleus) by benzopyran-4-one, dihydrobenzopyran or benzopyran-4-ol; (ii) the side chain at 2-position by shortening to C3, C4 and C5-carbons versus C-9-carbons of polycerasoidol; (iii) the carboxylic group (polar head) by oxygenated groups (hydroxyl, acetoxy, epoxide, ester, aldehyde) or non-oxygenated motifs (allyl and alkyl). Benzopyran-4-ones 6, 12, 13 and 17 as well as dihydrobenzopyrans 22, 24 and 25 were able to activate hPPARα, whereas benzopyran-4-one (7) with C5-carbons in the side chain exhibited hPPARγ agonism. According to our previous docking studies, SAR confirm that the hydrophobic nucleus (benzopyran-4-one or dihydrobenzopyran) is essential to activate PPARα and/or PPARγ, and the flexible linker (side alkyl chain) should containg at least C5-carbon atoms to activate PPARγ. By contrast, the polar head ("carboxylic group") tolerated several oxygenated groups but also non-oxygenated motifs. Taking into account these key structural features, small polycerasoidol analogs might provide potential active molecules useful in the treatment of dyslipidemia and/or type 2 diabetes.

Identifiants

pubmed: 31703893
pii: S0968-0896(19)31650-5
doi: 10.1016/j.bmc.2019.115162
pii:
doi:

Substances chimiques

Benzopyrans 0
PPAR alpha 0
PPAR gamma 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115162

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Almudena Bermejo (A)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain.

Isabel Barrachina (I)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain.

Noureddine El Aouad (N)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain.

Xavier Franck (X)

CNRS UMR 6014, C.O.B.R.A. & FR 3038, Université de Rouen, INSA de Rouen, 76131 Mont-Saint-Aignan Cedex, France.

Nadia Chahboune (N)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain.

Inmaculada Andreu (I)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain.

Bruno Figadère (B)

BioCIS, Université Paris-Sud, CNRS, Université Paris-Saclay, 92290 Châtenay-Malabry, France.

Laura Vila (L)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria - INCLIVA, Hospital Clínico Universitario de Valencia, Valencia 46010, Spain.

Nathalie Hennuyer (N)

Institut Pasteur de Lille, Univ. Lille - EGID, CHU Lille, Inserm U1011, F-59000 Lille, France.

Bart Staels (B)

Institut Pasteur de Lille, Univ. Lille - EGID, CHU Lille, Inserm U1011, F-59000 Lille, France.

Catherine Dacquet (C)

Institut de Recherches Servier, 92150 Suresnes, France.

Daniel H Caignard (DH)

Institut de Recherches Servier, 92150 Suresnes, France.

María-Jesús Sanz (MJ)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria - INCLIVA, Hospital Clínico Universitario de Valencia, Valencia 46010, Spain. Electronic address: maria.j.sanz@uv.es.

Diego Cortes (D)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain. Electronic address: dcortes@uv.es.

Nuria Cabedo (N)

Departamento de Farmacología, Universidad de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria - INCLIVA, Hospital Clínico Universitario de Valencia, Valencia 46010, Spain. Electronic address: ncabedo@uv.es.

Articles similaires

Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Neural Networks, Computer Drug Discovery Humans Drug Repositioning
Drug Design Models, Chemical Endopeptidase Clp Drug Discovery Humans

Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-

Alonzo González-González, Oscar Sánchez-Sánchez, Lilián Yépez-Mulia et al.
1.00
Giardia lamblia Trichomonas vaginalis Entamoeba histolytica Antiprotozoal Agents Quinoxalines

Classifications MeSH